1UK Prospective Diabetes Study Group. Overview of 6 years' therapy of type II diabetes:a progressive disease:UKPDS 16[J].Diabetes,1995.1249.doi:10.2337/diabetes.44.11.1249.
2Gandhi NR,NunnP,Dheda K. Multidrug-resistant and extensively drug-resistant tuberculosis:a threat to global control of tuberculosis[J].The Lancet,2010,(9728):1830.doi:10.1016/S0140-6736(10)60410-2.
3Creutzfeldt W. The[pre-] history of the incretin concept[J].Regulatory Peptides,2005.87.doi:10.1016/j.regpep.2004.08.004.
4Gautier JF,Choukem SP,Girard J. Physiology of incretins (GIPand GLP-1) and abnormalities in type 2 diabetes[J].Diabetes & Metabolism,2008,(Suppl 2):65.doi:10.1016/S1262-3636(08)73397-4.
5Baggio L L,Drucker D J. Clincal endocrinology and metabolism.Glucagon-like peptide-1 and glucagons-like peptide-2[J].Best Practice and Research:Clinical Endocrinology and Metabolism,2004,(04):531.doi:10.1016/j.beem.2004.08.001.
6Nauck MA,Heimesaat MM,Behle K. Effects of glucagon-like peptide 1 on counterregulatory hormone responses,cog-nitive functions,and insulin secretion during hyperinsulinemic,stepped hypoglycemic clamp experiments in healthy volunteers[J].J Clin Endocrine Merab,2002.1239.
7Deacon CF. Therapeutic strategies based on glucagon-like peptide1[J].Diabetes,2004,(09):2181.doi:10.2337/diabetes.53.9.2181.
8Grieve DJ,Cassidy RS,Green BD. Emerging cardiocascular actions of the incretin hormone glucagon-like peptide-1:potential therapeu-tic benefits beyond glycaemic control[J].British Journal of Pharmacology,2009,(08):1340.doi:10.1111/j.1476-5381.2009.00376.x.
9Iander M,Madsbad S,Madsen JL. Effect of 6 -week course of glucagon-like peptide 1 on glycaemic control,insulin sensitivity,andβ-cell function in type 2 diabetes:a parallel -group study[J].Lancet,2002,(05):824.doi:10.1016/j.visres.2009.02.010.
10Bregenholt S,Moldrup A,Blume N. The long-acting glucagon-like peptide-1 analogue,liraglutide,inhibits beta-cell apoptosis in vitro[J].Biochemical and Biophysical Research Communications,2005.577.
